ORPH - Orphazyme responds to extreme volatility

AndrewJohnson/E+ via Getty Images After over a fourfold rise value yesterday, Orphazyme ([[ORPH]] -44.3%) has lost more than a third so far in morning hours. Issuing a clarification, the company said that it was not aware of any reason that caused such extreme volatility in price and volume of its American Depositary Shares ((ADSs)) listed on Nasdaq US. “The company is not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume that has occurred since June 10, 2021,” Orphazyme said in the statement. It cautioned that “investors who purchase the company’s ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines.” Both Orphazyme and CytRx ([[CYTR]] -10.0%) spiked sharply yesterday as the companies await the FDA decision on Arimoclomol in the treatment of Niemann-Pick Disease Type

For further details see:

Orphazyme responds to extreme volatility